Cargando…

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer

Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Huaqiang, Liu, Jiaqing, Zhang, Yaxiong, Huang, Yan, Shen, Jiayi, Yang, Yunpeng, Fang, Wenfeng, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075870/ https://www.ncbi.nlm.nih.gov/pubmed/32195359 http://dx.doi.org/10.1038/s41698-020-0112-3

Ejemplares similares

Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019
por: Liu, Jiaqing, et al.
Publicado: (2020)

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
por: Fang, Wenfeng, et al.
Publicado: (2020)

A modifiable risk factors atlas of lung cancer: A Mendelian randomization study
por: Shen, Jiayi, et al.
Publicado: (2021)

Genetic Liability to Insomnia and Lung Cancer Risk: A Mendelian Randomization Analysis
por: Shen, Jiayi, et al.
Publicado: (2021)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Gut Microbiota and Lung Cancer: A Mendelian Randomization Study
por: Zhou, Huaqiang, et al.
Publicado: (2020)

Impact of prior cancer history on the overall survival of younger patients with lung cancer
por: Liu, Jiaqing, et al.
Publicado: (2020)

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
por: Yoo, Seong-Keun, et al.
Publicado: (2022)

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
por: Jelinic, Petar, et al.
Publicado: (2018)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms
por: Shen, Jiayi, et al.
Publicado: (2020)

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
por: Aili, Abudureyimujiang, et al.
Publicado: (2021)

Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes?
por: Zhang, Yaxiong, et al.
Publicado: (2019)

Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment
por: Loo, Kimberly, et al.
Publicado: (2022)

Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
por: Fox, Douglas B., et al.
Publicado: (2023)

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
por: Dai, Jiali, et al.
Publicado: (2023)

PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner
por: Zhou, Mi, et al.
Publicado: (2022)

Docosapentaenoic acid and lung cancer risk: A Mendelian randomization study
por: Liu, Jiaqing, et al.
Publicado: (2019)

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
por: Hastings, K, et al.
Publicado: (2019)

The maximum tumor growth rate predicts clinical outcomes of patients with small‐cell lung cancer undergoing first‐line chemotherapy plus immune‐checkpoint inhibitor therapy
por: Chen, Xiang, et al.
Publicado: (2023)

Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
por: Bolte, Laura A., et al.
Publicado: (2023)

Development and validation of a PBRM1‐associated immune prognostic model for clear cell renal cell carcinoma
por: Chen, Jiayi, et al.
Publicado: (2021)

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
por: Liu, Xian-De, et al.
Publicado: (2020)

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
por: Cooper, Zachary A., et al.
Publicado: (2016)

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
por: Riess, Jonathan W., et al.
Publicado: (2016)

Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB
por: Miao, Xia-ye, et al.
Publicado: (2022)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non‐small cell lung cancer
por: Lin, Zhihuan, et al.
Publicado: (2020)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Zhonghan, et al.
Publicado: (2020)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies
Publicado: (2016)

Role of tumor gene mutations in treatment response to immune checkpoint blockades
por: Wang, Manni, et al.
Publicado: (2019)

Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
por: Paglialunga, Luca, et al.
Publicado: (2016)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

Immune checkpoint blockade and biomarkers of clinical response in non–small cell lung cancer
por: Hallqvist, Andreas, et al.
Publicado: (2020)

Trends in incidence and associated risk factors of suicide mortality in patients with non‐small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_aa1miu0eciddqh9cmopcu1lad1